down arrow

Humana, Inc.

  • Market Cap: Mid Cap
  • Industry: Healthcare Services
  • ISIN: US4448591028
USD
253.02
-3.9 (-1.52%)

Dec 04

NYS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

251.03257.48

52 Week

206.87315.35
Valuation
Technical
Day's Volume

CASH

2.1 M

Shareholding (Mar 2025)

FII

18.79%

Held by 488 FIIs

DII

21.3%

Held by 76 DIIs

Promoter

0.10%

How big is Humana, Inc.?

22-Jun-2025

As of Jun 18, Humana, Inc. has a market capitalization of $46.07 billion, with recent net sales of $0 million and a net profit of $1.72 billion. The company reported shareholder's funds of $16.38 billion and total assets of $46.31 billion as of Dec 24.

Market Cap: As of Jun 18, Humana, Inc. has a market capitalization of 46,070.57 million, categorizing it as a Large Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Humana, Inc. reported net sales of 0.00 million and a net profit of 1,717.00 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 16,375.00 million and total assets of 46,312.00 million.

Read More

What does Humana, Inc. do?

22-Jun-2025

Humana, Inc. is a large-cap health and well-being company in the Healthcare Services industry, with a market cap of approximately $46.07 billion and a quarterly net profit of $1.24 billion. Key metrics include a P/E ratio of 26.00, a dividend yield of 3.78%, and a return on equity of 9.67%.

Overview: <BR>Humana, Inc. is a health and well-being company operating in the Healthcare Services industry, with a market capitalization in the large-cap bracket.<BR><BR>Financial Snapshot: <BR>Net Profit: 1,242 Million (Quarterly Results - Mar 2025) <BR>Market Cap: USD 46,070.57 Million (Large Cap)<BR><BR>Key Metrics: <BR>P/E: 26.00 <BR>Dividend Yield: 3.78% <BR>Debt Equity: -0.50 <BR>Return on Equity: 9.67% <BR>Price to Book: 2.60<BR><BR>Contact Details: <BR>Address: 500 W Main St, LOUISVILLE KY: 40202 <BR>Tel: ['1 502 5801000', '1 502 5802811'] <BR>Fax: 1 302 6365454 <BR>Website: http://www.humana.com/

Read More

Who are in the management team of Humana, Inc.?

22-Jun-2025

As of March 2022, Humana, Inc.'s management team includes Independent Chairman Kurt Hilzinger, CEO Bruce Broussard, and several Independent Directors: Frank Bisignano, Raquel Bono, Frank D'Amelio, Wayne Frederick, and John Garratt.

As of March 2022, the management team of Humana, Inc. includes the following individuals:<BR><BR>- Mr. Kurt Hilzinger, who serves as the Independent Chairman of the Board.<BR>- Mr. Bruce Broussard, who is the President, Chief Executive Officer, and a Director.<BR>- Mr. Frank Bisignano, serving as an Independent Director.<BR>- Dr. Raquel Bono, also an Independent Director.<BR>- Mr. Frank D'Amelio, another Independent Director.<BR>- Dr. Wayne Frederick, who is an Independent Director as well.<BR>- Mr. John Garratt, serving as an Independent Director.<BR><BR>In summary, as of March 2022, Humana, Inc.'s management team consists of a mix of independent directors and key executives, including the CEO and Chairman of the Board.

Read More

Is Humana, Inc. overvalued or undervalued?

20-Sep-2025

As of June 30, 2025, Humana, Inc. is considered overvalued with a P/E ratio of 26 compared to Centene Corp.'s 6.94, an EV to EBITDA of 37.39 versus Centene's 11.91, and has underperformed the S&P 500 with a 1-year return of -15.99% and a 3-year return of -47.01%.

As of 30 June 2025, Humana, Inc. has moved from expensive to very expensive, indicating a significant shift in its valuation outlook. The company is considered overvalued, with a P/E ratio of 26, which is substantially higher than its peer Centene Corp., which has a P/E of 6.94. Additionally, Humana's EV to EBITDA stands at 37.39, again reflecting a premium compared to Centene's 11.91, further supporting the overvaluation assessment. The price to book value is 2.48, suggesting that investors are paying a high price relative to the company's net assets.<BR><BR>In terms of recent performance, Humana has underperformed compared to the S&P 500, with a 1-year return of -15.99% versus the S&P 500's 17.14%, and a staggering 3-year return of -47.01% compared to the S&P 500's 70.41%. This trend reinforces the notion that the stock is overvalued in the current market context.

Read More

Is Humana, Inc. technically bullish or bearish?

05-Nov-2025

As of October 31, 2025, Humana, Inc. shows a mildly bullish technical trend, supported by bullish weekly MACD and daily moving averages, but tempered by mixed signals from the weekly KST and monthly Bollinger Bands, while underperforming the S&P 500 year-to-date and over the past year.

As of 31 October 2025, the technical trend for Humana, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a mildly bullish stance. However, the weekly KST is mildly bearish, and the Bollinger Bands show a mildly bearish signal on the monthly timeframe. The Dow Theory reflects a mildly bullish trend on the weekly basis but shows no trend monthly.<BR><BR>In terms of performance, Humana has underperformed the S&P 500 across multiple periods, with a year-to-date return of 11.10% compared to the S&P 500's 16.30%, and a one-year return of 8.12% against the S&P 500's 19.89%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals from various indicators.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 17.30%

 
2

The company declared positive results in Mar'25 after very negative results in Dec'24

3

With ROE of 9.67%, it has a very expensive valuation with a 2.48 Price to Book Value

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Healthcare Services

stock-summary
Market cap

USD 59,092 Million (Mid Cap)

stock-summary
P/E

26.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

2.16%

stock-summary
Debt Equity

-0.50

stock-summary
Return on Equity

8.68%

stock-summary
Price to Book

3.24

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
543 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.9%
0%
-18.9%
6 Months
9.61%
0%
9.61%
1 Year
-12.17%
0%
-12.17%
2 Years
-48.57%
0%
-48.57%
3 Years
-53.73%
0%
-53.73%
4 Years
-40.0%
0%
-40.0%
5 Years
-38.7%
0%
-38.7%

Humana, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Humana, Inc. Stock Hits Day Low Amid Price Pressure, Reaches $251.16

Humana, Inc. Stock Hits Day Low Amid Price Pressure, Reaches $251.16

Humana, Inc. faced a notable stock decline today, reaching an intraday low and reflecting a challenging market environment. Despite a recent net profit report indicating positive momentum, the company's stock has underperformed compared to the S&P 500 over the past year, raising concerns about its valuation metrics.

Read More

Is Humana, Inc. technically bullish or bearish?

As of 31 October 2025, the technical trend for Humana, Inc. has changed from bullish to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish. The daily moving averages indicate a mildly bullish stance. However, the weekly KST is mildly bearish, and the Bollinger Bands show a mildly bearish signal on the monthly timeframe. The Dow Theory reflects a mildly bullish trend on the weekly basis but shows no trend monthly. In terms of performance, Humana has underperformed the S&P 500 across multiple periods, with a year-to-date return of 11.10% compared to the S&P 500's 16.30%, and a one-year return of 8.12% against the S&P 500's 19.89%. Overall, the current technical stance is mildly bullish, but the strength is tempered by mixed signals from various indicators....

Read More
Humana, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators

Humana, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Indicators

Humana, Inc. has recently revised its evaluation amid fluctuating market conditions, with its stock showing a slight increase. Over the past year, the company has experienced significant trading activity. Despite some mixed technical indicators, Humana's returns have lagged behind the S&P 500 across various time frames, reflecting ongoing challenges.

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
11.77%
EBIT Growth (5y)
0
EBIT to Interest (avg)
0.11
Debt to EBITDA (avg)
14.09
Net Debt to Equity (avg)
0.75
Sales to Capital Employed (avg)
3.75
Tax Ratio
23.69%
Dividend Payout Ratio
35.45%
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
17.30%
Valuation key factors
Factor
Value
P/E Ratio
26
Industry P/E
Price to Book Value
2.48
EV to EBIT
NA
EV to EBITDA
37.39
EV to Capital Employed
3.95
EV to Sales
0.29
PEG Ratio
NA
Dividend Yield
3.95%
ROCE (Latest)
ROE (Latest)
9.67%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bullish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 191 Schemes (59.81%)

Foreign Institutions

Held by 488 Foreign Institutions (18.79%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -56.28% vs 281.84% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "211.00",
          "val2": "215.00",
          "chgp": "-1.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "157.00",
          "val2": "160.00",
          "chgp": "-1.88%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "543.00",
          "val2": "1,242.00",
          "chgp": "-56.28%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "33.90%",
          "val2": "62.70%",
          "chgp": "-2.88%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -51.13% vs -11.35% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "968.00",
          "val2": "917.00",
          "chgp": "5.56%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "660.00",
          "val2": "493.00",
          "chgp": "33.87%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-200.00",
          "val2": "-125.00",
          "chgp": "-60.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,214.00",
          "val2": "2,484.00",
          "chgp": "-51.13%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "23.40%",
          "val2": "38.90%",
          "chgp": "-1.55%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
211.00
215.00
-1.86%
Interest
157.00
160.00
-1.88%
Exceptional Items
0.00
0.00
Consolidate Net Profit
543.00
1,242.00
-56.28%
Operating Profit Margin (Excl OI)
33.90%
62.70%
-2.88%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -56.28% vs 281.84% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
968.00
917.00
5.56%
Interest
660.00
493.00
33.87%
Exceptional Items
-200.00
-125.00
-60.00%
Consolidate Net Profit
1,214.00
2,484.00
-51.13%
Operating Profit Margin (Excl OI)
23.40%
38.90%
-1.55%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -51.13% vs -11.35% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Humana, Inc. stock-summary
stock-summary
Humana, Inc.
Healthcare Services
Humana Inc. is a health and well-being company. The Company's segments include Retail, Group and Specialty, Healthcare Services and Individual Commercial. The Retail segment consists of Medicare benefits, including dental, vision, and other supplemental health and financial protection products. The Healthcare Services segment includes services offered to its health plan members, as well as to third parties, including pharmacy solutions, provider services, home-based services and clinical programs, as well as services and capabilities to manage population health. The Individual Commercial segment includes Individual Commercial products marketed under the HumanaOne brand.
Company Coordinates stock-summary
Company Details
500 W Main St , LOUISVILLE KY : 40202
stock-summary
Tel: 1 502 58010001 502 5802811
stock-summary
http://www.humana.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."